Beta Bionics Inc., a commercial-stage medical technology company focused on advanced diabetes management solutions, has priced its initial public offering of 12 million shares of common stock at $17.00 each.
Beta Bionics shares will begin trading on the Nasdaq on January 30, 2025, under the symbol "BBNX."
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com